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Background: The incretin hormone GLP-1 and its analogue exendin-4 are known to boost glucose utilization in skeletal muscle and adipose 
tissues, possibly accounting for their therapeutic effects in insulin resistance. We assessed the effects of both GLP-1 and exendin-4 on myocardial 
glucose uptake (GU), glucose oxidation (GO) and contractility.
Methods: Rat hearts were perfused with buffer containing only glucose (5mM) or glucose (5mM) and oleate (0.4mM) for 60 minutes in the working 
mode. After 30 minutes, GLP-1 or exendin-4 (0.5 nM or 5 nM) was added. We measured changes in cardiac GU ([2-3H] glucose) and GO ([U-14C] 
glucose).
Results: In the absence of oleate, 5nM GLP-1 elevated GU (4.68±0.29 vs. 3.85±0.44 μmolglc/min/gdry, p<0.05) and GO (2.78±0.35 vs. 1.86±0.4, 
p<0.01). Exendin-4 increased GO at both 0.5 nM (4.84±0.76 vs. 4.02±0.76 μmolglc/min/gdry, p<0.05) and 5nM (3.67±0.71 vs. 3.03±0.84 
μmolglc/min/gdry, p<0.05). Neither GLP-1 nor exendin-4 showed any effect on cardiac power. However, in the presence of oleate, GLP-1 did not 
change glucose utilization and exendin-4 unexpectedly decreased GU at both 0.5nM (0.64±0.07 vs. 1.91±0.19 μmolglc/min/gdry, p<0.001) and 
5nM (1±0.15 vs. 1.82±0.11, p<0.05). Besides, both 5nM GLP-1 (15.1±1.4 vs. 25.97±3.73 mW/gdry, p<0.05) and exendin-4 at 0.5 nM (25.18±3.5 
vs. 30.89±4.21 mW/gdry, p<0.05) or 5nM (26.58±3.15 vs. 35.19±0.77 mW/gdry, p<0.05) diminished cardiac power.
Conclusions: Oleate at physiological concentration masks the stimulating effects of GLP-1 and exendin-4 on myocardial glucose utilization and 
even causes exendin-4 to depress cardiac GU. We also suggest that oleate utilization is involved in the negative inotropic effects of both peptides.
